What is the appropriate treatment for a patient with thrombocytosis (platelet count 736 × 10⁹/L) and neuropathy?

Treatment Recommendation for Thrombocytosis (736 × 10⁹/L) with Neuropathy

For a patient with a platelet count of 736 × 10⁹/L and neuropathy, initiate low-dose aspirin immediately and start cytoreductive therapy with hydroxyurea if the patient is high-risk (age >60 years or prior thrombosis history), as the neuropathy represents a microvascular complication requiring urgent platelet reduction.

Risk Stratification and Treatment Algorithm

The presence of neuropathy in this patient is a critical finding that changes management. Neuropathies (paresthesias) are well-documented microvascular manifestations of essential thrombocythemia and indicate active platelet-mediated vascular complications 1, 2.

Immediate Actions:

Start low-dose aspirin (81-100 mg daily) immediately for all patients with thrombocytosis, regardless of risk category 2. If the patient has microvascular symptoms like neuropathy, consider twice-daily dosing 2.

Determine Risk Category:

The patient's risk stratification determines cytoreductive therapy need:

• High-risk: Age >60 years OR prior thrombosis history → Cytoreduction mandatory
• Intermediate-risk: Age >60 years with JAK2 wild-type → Cytoreduction optional but strongly consider given neuropathy
• Low-risk: Age ≤60 years with JAK2 mutation → Cytoreduction optional but strongly consider given neuropathy
• Very low-risk: Age ≤60 years, no thrombosis, JAK2 wild-type → Cytoreduction optional but strongly consider given neuropathy

2

Cytoreductive Therapy Indication

The presence of neuropathy itself is an indication for cytoreductive therapy, even in otherwise lower-risk patients. The European LeukemiaNet guidelines specifically note that "symptomatic or progressive" disease manifestations warrant cytoreduction 3. Neurologic symptoms in essential thrombocythemia, including paresthesias, respond satisfactorily to treatment with megakaryocyte suppression 1.

First-Line Cytoreductive Agent:

Hydroxyurea is the first-line cytoreductive therapy 3, 2.

• Start at 15-20 mg/kg/day, adjust based on platelet response
• Target platelet count: <400-450 × 10⁹/L
• Monitor CBC weekly initially, then every 2-4 weeks once stable

Alternative first-line option: Pegylated interferon-α, particularly if:

• Patient is young (<40 years) and concerned about long-term hydroxyurea exposure
• Patient is pregnant or planning pregnancy
• Patient has intolerance to hydroxyurea

3, 2

Important Clinical Considerations

The Platelet Count Paradox:

While the platelet count of 736 × 10⁹/L is elevated, the absolute platelet number is less predictive of thrombotic risk than the presence of symptoms 4. The neuropathy indicates that microvascular complications are already occurring, making this a symptomatic case requiring treatment regardless of the specific platelet number.

Neurologic Symptoms Response:

All patients with neurologic manifestations in the historical literature responded satisfactorily to treatment, though continuous or repeated therapy was often required 1. This supports aggressive initial management.

Cardiovascular Risk Factor Management:

Aggressively manage all cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, smoking) as these compound thrombotic risk 3, 2.

Common Pitfalls to Avoid:

1. Don't wait for platelet counts >1500 × 10⁹/L to start treatment - symptomatic disease (neuropathy) is an indication regardless of platelet count 3

2. Don't attribute neuropathy to other causes without treating the thrombocytosis - neurologic symptoms are well-established complications of essential thrombocythemia 1, 5

3. Don't use platelet count alone to guide treatment - the presence of microvascular symptoms (neuropathy, headaches, paresthesias) is more important than the absolute number 4, 2

4. Don't forget aspirin - even with cytoreduction, aspirin remains essential for preventing microvascular complications 2

Diagnostic Workup Required:

Before finalizing treatment, confirm this is essential thrombocythemia versus secondary thrombocytosis:

• JAK2 V617F mutation testing (positive in ~60% of ET)
• If JAK2 negative: CALR and MPL mutation testing
• Bone marrow biopsy to exclude prefibrotic myelofibrosis and confirm diagnosis
• C-reactive protein and ferritin to exclude reactive thrombocytosis
• Peripheral blood smear to assess morphology

6, 2

If this is secondary (reactive) thrombocytosis, treat the underlying cause and the neuropathy may have an alternative etiology. However, given the platelet count and neuropathy combination, essential thrombocythemia is the leading diagnosis.